Oral treatments for HAE

Aimed at helping patients suffering from this rare, potentially life-threatening disease.

A rare but serious disease

Hereditary angioedema (HAE), categorized as an Orphan Disease by the FDA and EMA, is a rare genetic disease characterized by recurring episodes of swelling, which can be life-threatening if they affect the airways.

A less invasive treatment option

While current HAE drugs rely on intravenous or subcutaneous injections, we are developing our HAE drug candidates for oral dosing and have shown good efficacy in preclinical studies.

Oral drugs could be more affordable and are expected to have a significant positive impact on the lives of HAE patients, especially for ongoing disease prophylaxis.